{
  "nodes": [
    {
      "id": "node_001",
      "content": "Stage IIIB (T1–2, N3)\nStage IIIC (T3, N3)",
      "parent_ids": [],
      "children_ids": [
        "node_002"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_002",
      "content": "• Molecular testing for EGFR\n• PFTs (if not previously done)\n• FDG-PET/CT scan (if not previously done)\n• Brain MRI with contrast\n• Pathologic confirmation of N3 disease by:\n‣ Mediastinoscopy\n‣ Supraclavicular lymph node biopsy\n‣ Thoracoscopy\n‣ Needle biopsy\n‣ Mediastinotomy\n‣ EUS biopsy\n‣ EBUS biopsy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_003",
        "node_004",
        "node_005"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "k",
        "r"
      ]
    },
    {
      "id": "node_003",
      "content": "N3 negative",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_004",
      "content": "N3 positive",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_007"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_005",
      "content": "Metastatic disease",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_008"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_006",
      "content": "Initial treatment for stage I–IIIA (NSCL-8)",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-8"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_007",
      "content": "Definitive concurrent chemoradiation (category 1)",
      "parent_ids": [
        "node_004"
      ],
      "children_ids": [
        "node_009"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "n",
        "t"
      ]
    },
    {
      "id": "node_008",
      "content": "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
      "parent_ids": [
        "node_005"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-15",
        "NSCL-18"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_009",
      "content": "Durvalumab (if no EGFR exon 19 deletion or L858R) (category 1)\nor\nOsimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
      "parent_ids": [
        "node_007"
      ],
      "children_ids": [
        "node_010"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "t",
        "v"
      ]
    },
    {
      "id": "node_010",
      "content": "Surveillance (NSCL-17)",
      "parent_ids": [
        "node_009"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-17"
      ],
      "footnote_labels": []
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-13",
      "to_tree": "NSCL-8",
      "description": "Initial treatment for stage I–IIIA"
    },
    {
      "from_tree": "NSCL-13",
      "to_tree": "NSCL-15",
      "description": "Treatment for Metastasis limited sites"
    },
    {
      "from_tree": "NSCL-13",
      "to_tree": "NSCL-18",
      "description": "Treatment for Metastasis distant disease"
    },
    {
      "from_tree": "NSCL-13",
      "to_tree": "NSCL-17",
      "description": "Surveillance"
    },
    {
      "from_tree": "NSCL-13",
      "to_tree": "NSCL-C",
      "description": "Principles of Radiation Therapy (referenced in footnote n)"
    },
    {
      "from_tree": "NSCL-13",
      "to_tree": "NSCL-F",
      "description": "Concurrent Chemoradiation Regimens (referenced in footnote t)"
    }
  ],
  "footnotes": [
    {
      "label": "k",
      "content": "FDG-PET/CT performed skull base to mid-thigh. Positive FDG-PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If FDG-PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation."
    },
    {
      "label": "n",
      "content": "Principles of Radiation Therapy (NSCL-C)."
    },
    {
      "label": "r",
      "content": "If MRI is not possible, CT of head with contrast."
    },
    {
      "label": "t",
      "content": "Concurrent Chemoradiation Regimens (NSCL-F)."
    },
    {
      "label": "v",
      "content": "For patients who have received sequential chemoradiation, durvalumab can be considered as consolidation immunotherapy or, if EGFR exon 19 deletion or L858R, osimertinib is recommended."
    }
  ],
  "extraction_confidence": 1.0,
  "image_title": "NCCN Guidelines Version 3.2025 Non-Small Cell Lung Cancer",
  "tree_id": "NSCL-13",
  "keywords": [
    "osimertinib",
    "durvalumab",
    "EGFR"
  ]
}
